LBT
Director Trades
| Date | Director | Value |
|---|
Company News
Weekly wrap: markets enter a new era after incredible volatility
After an absolutely hectic and volatile week on the world’s share markets, it is tempting to say well, that’s over now and things have settled down. On the surface that may be true, particularly when you consider that the ASX 200 is only down 2% for the week but it doesn’t factor in the fact […]
LBT Innovations signs $4.1m deal with AstraZeneca for supply of APAS Independence kits
Australian medical technology company LBT Innovations (ASX: LBT) has signed a $4.1 million deal to supply its APAS (automated plate assessment system) Independence kits plus support and maintenance services to global biopharmaceutical company and development partner AstraZeneca. The seven-year contract will see the first five instruments supplied and installed across a number of AstraZeneca’s large […]
Market wrap: banks drag ASX 200 lower but miners provide strength
Investors continued to bail out of bank stocks, dragging the ASX 200 index lower despite some positive news for the big miners on the back of a stronger copper price. The strong rally in bank share prices that saw most of them hit multi-year highs just a week ago is nothing but a memory now, […]
LBT Innovations confirms APAS PharmaQC ready for sale to global biopharma markets
LBT Innovations (ASX: LBT) has announced that its APAS (Automated Plate Assessment System) PharmaQC technology for automated imaging, analysis and interpretation of microbiology culture plates is ready for sale to global markets. The announcement follows the completion of primary validation testing, the final stage in the commercialisation process with product development partner AstraZeneca. Testing was […]
LBT Innovations to partner with AstraZeneca on development of APAS Pharma microbial monitoring product
Australian medical technology company LBT Innovations (ASX: LBT) will partner with global biopharmaceutical firm AstraZeneca for the full product development of its APAS Pharma artificial intelligence software. The $1 million project will see LBT develop the Automated Plate Assessment System (APAS) analysis module for use by AstraZeneca in identifying microbial growth on settle plates used […]
LBT Innovations signs Beckman Coulter to market APAS Independence throughout Europe
Australian medical technology company LBT Innovations (ASX: LBT) has signed a marketing agreement with clinical diagnostics specialist Beckman Coulter for the sale of its culture-plate screening and interpretation technology throughout Europe. Under the terms of the three-year strategic partnership, Beckman will act as marketing agent for LBT’s automated plate assessment system known as APAS Independence, which uses […]
LBT Innovations makes first APAS sale in EU to Germany’s largest clinical laboratory
Australian medical technology company LBT Innovations (ASX: LBT) has announced the first sale of its APAS (Automatic Plate Assessment System) Independence instrument within the European Union, to Germany’s largest clinical laboratory Labor Dr Wisplinghoff. The sale was completed following CE Mark certification and full integration into Labor Dr Wisplinghoff’s laboratory workflow to support routine clinical […]
LBT Innovations receives green light for EU market entry, completes MRSA clinical study
Medical technology company LBT Innovations (ASX: LBT) is set to take its artificial intelligence-inspired APAS Independence instrument to Europe after obtaining the highly prized CE Mark certification – a stamp of regulatory approval issued to products allowing their sale across the European continent. The APAS instrument – or Automated Plate Assessment System – is based […]
LBT Innovations receives FDA clearance to commercialise pathology screening device in US market
Australian medical technology company LBT Innovations (ASX: LBT) has received pre-market 510(k) clearance from the US Food and Drug Administration for its APAS (Automated Plate Assessment System) Independence autonomous medical device with associated urine analysis module. The clearance was achieved through the Clever Culture Systems (CCS) joint venture – held 50:50 by LBT and German […]
LBT Innovations completes first sale of APAS Independence
LBT Innovations (ASX: LBT) has announced the first sale of the company’s Automated Plate Assessment System (APAS) Independence instrument to a major hospital. Earlier today, the medical technology company said it had secured the first commercial sale of its APAS Independence system to St Vincent’s Hospital in Melbourne, after successfully completing a six-week independent evaluation […]
